Phase 4 N=31 Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
Diabetes
Primary: HbA1c at Three Months of Each Period of Treatment — 10.7; 11.2; 7.8; 7.3 percentage (DCCT unit)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=481 Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle
Influenza · Respiratory Viral Infection
Primary: Initiate Antiviral Therapy Within 48 Hours of Symptom Onset — 8 Participants
Phase 4 N=13 New Onset Type 1 Diabetes: Role of Exenatide
Type 1 Diabetes
Primary: The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.
Phase 4 N=63 Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria
Idiopathic Focal Segmental Glomerulosclerosis
Primary: Number of Participants With Adverse Events — 0; 11; 60 Participants
Phase 4 N=31 ProvodineTM Decreases Hand Contamination
Hand Hygiene
Primary: Control Period-Count the Number of Baseline Colony Forming Units Cultured From Anesthesiologist's Hands — 589.3 Colony forming units
Phase 4 N=25 Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B
Hemophilia B
Primary: Percentage of Participants Who Developed Factor IX (FIX) Inhibitors — 0 Percentage of participants
Phase 4 N=20 Sexual Absorption of Vaginal Progesterone
Infertility · Pregnancy
Primary: Female Change in Progesterone — 0.8; 7.0 ng/ml
Phase 4 N=60 A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT™ With Lidocaine for Lip Augmentation
Lip Augmentation
Primary: Percentage of Participants With a ≥ 1-point Improvement (Increase) in the Lip Fullness Scale (LFS2) Compared to Baseline Assessment at Day 30 — 93.2 percentage of…
Phase 4 N=316 Belatacept Early Steroid Withdrawal Trial
Renal Transplantation
Primary: # Patients With Composite Endpoint of Experiencing Either Death, Graft Loss, or eGFR < 45ml/Min — 9; 15; 14 Participants
Phase 4 N=39 A Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism
Chronic Hypoparathyroidism · Hypoparathyroidism
Primary: Change From Baseline (402) in Concentration of Albumin-corrected Serum Calcium (ACSC) at Month 6 — -0.005 Millimole per liter (mmol/L)
Phase 4 N=46 Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy
Endocrine Dysfunction · Trauma · Brain Injury
Primary: Restricted Functional Independence Measure (FIM) — 34; 16; 21; 52 units on a scale — p=0.9540
Phase 4 N=1,062 Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409
Relapsing Remitting Multiple Sclerosis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), and Treatment-Emergent Serious Adverse Events (TESAEs) — 204; 500; 879; 55 Participants
Phase 4 N=15 TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants
Phase 4 N=110 Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium
Atherosclerosis
Primary: Coronary Artery Calcium (Serial Calcium Scans) — 26.3; 40.5 mm cubed
Phase 4 N=36 Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty
Femoral Neck Fractures
Primary: Number of Participants Who Needed Transfusions — 0; 5 Participants